Icosapent ethyl provides ‘consistent benefit’ in patients with, without prior PAD

icosapent ethyl provides consistent benefit in patients with without prior pad

Sumary of Icosapent ethyl provides ‘consistent benefit’ in patients with, without prior PAD:

  • Presentation RF181. Presented at: American Heart Association Scientific Sessions;
  • Back to Healio New analyses from the REDUCE-IT study show icosapent ethyl significantly reduced total primary CV endpoints by 32% in patients with prior peripheral artery disease, suggesting substantial benefit for a high-risk population.
  • The data were presented at the American Heart Association Scientific Sessions.
  • data from the REDUCE-IT trial show participants with a baseline history of PAD were much more likely to experience first and total primary endpoints over 5 years — a combination of CV death, MI, stroke, coronary revascularization and unstable angina — vs.
  • Bhatt “If you look at risk for total events among the patients with peripheral artery disease in REDUCE-IT, it is actually rather staggering, 98.2%,” Cardiology Today Intervention Section Editor Deepak L.
  • Bhatt, MD, MPH, executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, said in an interview.
  • ” As Healio previously reported, the main REDUCE-IT findings demonstrated icosapent ethyl (Vascepa, Amarin), a pharmaceutical-grade omega-3 fatty acid, was superior to placebo for reducing risk for ischemic events in patients with elevated triglycerides at high CV risk despite statin therapy.
  • Patients were assigned icosapent ethyl 2 g twice daily or placebo and followed for a median of 4.9 years.

Want to know more click here go to source.

From -


Site Language

Popular Posts


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.